# GLP-1 Medication Guide: Options Compared | CED Clinic > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/metabolic/metabolic-glp1-guide/ > **Published:** 2026-04-08T01:19:56-04:00 | **Last Modified / Clinically Audited:** 2026-10-24T11:49:05-04:00 > **Clinical Summary:** Comprehensive physician comparison of semaglutide, tirzepatide, and oral peptides. Dosage ladders, clinical trials, and brand vs compounded guidance. --- [Overview](/metabolic/) [How It Works](/metabolic/metabolic-how-it-works/) [Practical Steps](/metabolic/metabolic-practical-steps/) [Medications](/metabolic/metabolic-medications/) [Full Guide](/metabolic/metabolic-glp1-guide/) [FAQ](/metabolic/metabolic-faq/) [About](/metabolic/metabolic-about/) [Book](/metabolic/metabolic-book/) [Book a Consultation](/metabolic/metabolic-book/) **Want a physician-guided plan instead of sorting through all of this alone?** [Book Starting Visit](/metabolic/metabolic-book/) [See Visit Options](#book-with-ced) Oxford CEBM Level 1A: Systematic Reviews of Randomized Controlled Trials & FDA Labeling CED Metabolic Guide # GLP-1 medications, made easier to compare This page is built to help patients make sense of the major decision lines: which molecule, which brand, injection versus pill, FDA-approved versus non-approved, introductory dosing versus full maintenance dosing, how closely you want to be followed, and what kind of treatment relationship you actually want. ### Quick Summary: GLP-1 & GIP Dual Agonist Comparison GLP-1 receptor agonists and dual GLP-1/GIP co-agonists are evidence-grounded pharmacotherapies for type 2 diabetes and chronic [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/). Branded medications including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) demonstrate 15% to 22.5% mean weight reduction in randomized trials when combined with physician-guided titration, behavioral adjustments, and continuous clinical oversight. Primary Drug ClassesSingle GLP-1 receptor agonists (semaglutide) & dual GLP-1/GIP agonists (tirzepatide) Clinical Efficacy14.9% mean weight loss (STEP-1 semaglutide) vs 20.9% (SURMOUNT-1 tirzepatide) Delivery FormatsSubcutaneous weekly injections & daily oral peptide tablets Safety DistinctionFDA-approved branded products vs non-approved compounded formulations Evidence BaselineOxford CEBM Level 1A trial data & 350,000+ lifetime clinical evaluations **Clinical Consensus:** Content verified by Dr. Benjamin Caplan, MD, Diplomate of the American Board of Family Medicine (ABFM), referencing FDA prescribing guidelines, NEJM clinical trial literature, and the CED Command Center repository. The goal is clarity, not hype. Some options are FDA-approved branded medications. Others are compounded or non-approved versions that may look similar on the surface but are not regulated the same way. Those are not interchangeable categories. FDA-approved products clearly marked Non-FDA-approved options separated out Pills and injections both included Microdosing explained [Book Your Starting Visit](/metabolic/metabolic-book/) [Compare the medications](#molecules) PHYSICIAN-LED GLP-1 PRACTICE • DR. BENJAMIN CAPLAN, MD ## A Faster Way to Sort Out What Fits Skip generic marketing portals. Meet 1-on-1 with a board-certified physician for personalized medical evaluation, titration, and long-term care. STEP 1 • RECOMMENDED FIRST VISIT ### GLP-1 Starting Visit / Onboarding $100 • 15 min A personalized first visit to review options, risks, expectations, your health history, and personalized treatment plan with Dr. Caplan. [Book Starting Visit →](/metabolic/metabolic-book/) STEP 2 • WEEKS 4 TO 12 ### GLP-1 Early Check-In / Optimization $100 • 15 min A focused follow-up to review appetite, [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/), tolerance, response, timing, and dose titration with your physician. [Book Early Check-In →](/metabolic/metabolic-book/) STEP 3 • ONGOING MAINTENANCE ### GLP-1 Progress + Maintenance $100 • 15 min An ongoing follow-up for durable progress, practical troubleshooting, and treatment refinement over time. [Book Maintenance Visit →](/metabolic/metabolic-book/) **4** FDA-approved molecules now available: semaglutide, tirzepatide, liraglutide, and orforglipron. **2** Main delivery formats: injections and tablets. Oral options now exist for semaglutide and orforglipron. **1** Very important divide: FDA-approved branded products versus compounded or non-FDA-approved products. These are not the same category. **Many** Ways to access care, from low-touch telehealth prescribing to relationship-based clinical follow-up with active titration. ## Quick navigation [Molecule choices](#molecules) [Dose ranges](#doses) [Pills vs injections](#oral-vs-injectable) [Approved vs non-approved](#approved-vs-not) [Ways to obtain GLP-1s](#access-models) [Monitoring and follow-up](#monitoring) [Duration of treatment](#duration) [Practical Steps Roadmap](/metabolic/metabolic-practical-steps/) [Book with Dr. Caplan](#book-with-ced) ## Molecule choices Start here. Most people first need to know the molecule name, the company behind it, the brand name, and whether it comes as an injection, a pill, or both. FDA-approved brands shown **Semaglutide** Novo Nordisk FDA-approved Weekly injection Daily oral tablet **Wegovy** (weight management) • **Ozempic** (diabetes, cardiovascular risk) • **Rybelsus / oral Wegovy** (diabetes and weight pathways) The semaglutide family spans obesity-focused and diabetes-focused products. Brand name matters because the indication and dose ladder differ even when the molecule is the same. **Tirzepatide** Eli Lilly FDA-approved Weekly injection **Zepbound** (weight management, obstructive sleep apnea with obesity) • **Mounjaro** (type 2 diabetes) Tirzepatide acts on both GIP and GLP-1 pathways, making it dual-acting. Head-to-head data shows among the highest average weight loss of any approved agent. Often discussed alongside GLP-1s even though it is technically different. **Liraglutide** Novo Nordisk FDA-approved Daily injection **Saxenda** (weight management) • **Victoza** (type 2 diabetes) An older but still relevant option. Requires daily injection rather than weekly, which creates a different adherence experience. Generally produces less weight loss than newer weekly agents in clinical comparisons. **Orforglipron** Eli Lilly FDA-approved Daily oral tablet **Foundayo** (chronic weight management in adults with obesity or overweight with at least one weight-related condition) A newer oral GLP-1 that is its own molecule, not semaglutide. It offers a true pill-based path for weight management without any injection requirement. **Simple takeaway:** brand names are not just marketing labels. They can signal a different indication, a different dose ladder, and a different regulatory pathway even when the active molecule overlaps. ## Dose ranges, from introductory to full maintenance Most GLP-1 treatment begins with a lower introductory dose and builds gradually as tolerated. Some low doses are official FDA-labeled starting doses. Very low custom “microdoses” marketed online are not part of any FDA-approved labeled regimen. FDA-approved labeled dose step Often used as introductory titration Custom microdose or compound, not FDA-approved **Wegovy injection** Semaglutide • Weekly injection FDA-approved Introductory 0.25 mg weekly Then 0.5 mg, 1 mg, 1.7 mg at 4-week steps Maintenance 1.7 mg or 2.4 mg weekly The low starting dose is an official ramp-up step, not a maintenance goal for most patients. **Wegovy tablets** Semaglutide • Daily oral tablet FDA-approved Introductory 1.5 mg daily Then 4 mg, then 9 mg Maintenance 25 mg daily Oral semaglutide for weight management uses a distinct dose ladder and should not be assumed equivalent to injectable dosing. **Zepbound** Tirzepatide • Weekly injection FDA-approved Introductory 2.5 mg weekly Maintenance 5 mg, 10 mg, or 15 mg weekly The 2.5 mg dose is a starting dose, not a chronic maintenance dose for most weight-management use. **Mounjaro** Tirzepatide • Weekly injection FDA-approved Introductory 2.5 mg weekly Maintenance 5 mg to 15 mg weekly Same molecule family as Zepbound, but the brand and FDA indication differ (diabetes vs. weight management). **Ozempic injection** Semaglutide • Weekly injection FDA-approved Introductory 0.25 mg weekly Maintenance 0.5 mg, 1 mg, or 2 mg weekly Semaglutide for diabetes and cardiovascular risk reduction. Not the same labeled indication as Wegovy. **Rybelsus** Semaglutide • Daily oral tablet FDA-approved Introductory 3 mg daily Maintenance 7 mg or 14 mg daily Oral semaglutide for diabetes. Its dosing should not be borrowed for obesity care without regard to indication. **Saxenda** Liraglutide • Daily injection FDA-approved Introductory 0.6 mg daily Increased by 0.6 mg weekly Maintenance 3 mg daily A daily pen rather than a weekly one. That may appeal to some patients and less so to others. **Foundayo** Orforglipron • Daily oral tablet FDA-approved Introductory 0.8 mg daily Then 2.5 mg, then 5.5 mg Maintenance 9 mg to 17.2 mg daily A true oral GLP-1 for weight management. Its own molecule and dose ladder, distinct from semaglutide oral forms. **Custom “microdose” programs** Molecule and form varies Not FDA-approved Introductory Below-labeled custom doses Maintenance Often individualized and non-standard May be marketed as gentler or cheaper. Not automatically FDA-approved simply because they resemble a known molecule. **Important distinction:** “microdosing” is a real word in the marketplace, but it is not itself an FDA-approved indication or standardized regulatory category. Beginning on a low, labeled starter dose of an FDA-approved product is very different from a custom compounded low-dose pathway sold outside the FDA approval system. ## Oral versus injectable options For some people, the biggest decision is not the molecule but the format. Pills may feel easier and more familiar. Injections may offer a different potency pathway or adherence experience. Injectable options ### Weekly or daily injections **Wegovy**, **Zepbound**, **Ozempic**, **Mounjaro**, **Saxenda**, and **Victoza** are injectable products. Weekly injections can feel simpler for adherence, while daily injections allow a different rhythm but can feel more demanding over time. Oral options ### Tablet pathways now matter much more **Wegovy tablets**, **Rybelsus**, **Ozempic tablets**, and **Foundayo** make pill-based treatment a real category rather than a fringe alternative. This matters for people who dislike needles, travel often, or want a simpler daily routine. Best fit depends on goals ### Convenience is not the only variable The right choice also depends on indication, cost, insurance coverage, potency expectations, side-effect tolerance, and whether someone values faster escalation, slower titration, or easier day-to-day use. ## FDA-approved products versus non-FDA-approved options This is one of the most important sections on the page. Some products are FDA-approved branded medications with known labeled doses, established manufacturing oversight, and formal prescribing information. Others are not. FDA-approved ### Branded, labeled, regulated These products have reviewed labeling, approved dose ladders, recognized indications, and standardized manufacturing expectations. That does not make them perfect or risk-free. It does mean the regulatory path is clear. - Known brand and manufacturer - Known FDA labeling and dose steps - Known approved indication - Pharmacy distribution through standard channels Compounded or custom-mixed ### Often cheaper, often less standardized Compounded GLP-1 products are not FDA-approved. Some programs also combine the active chemistry with extra ingredients, fillers, vitamins, or alternate forms of the molecule. These may be marketed aggressively, but they are not the same as an FDA-approved product by brand. - Not reviewed by FDA as approved finished products - May differ in concentration, excipients, or formulation - May be presented under a telehealth brand rather than the actual compounder - May be used for custom microdosing pathways that are not on the FDA label What patients often miss ### “Looks similar” is not the same as “is the same” A website can make a product appear equivalent to a branded GLP-1 even when the product source, approval status, concentration, and oversight are fundamentally different. That distinction matters when the goal is safe, sustainable, and transparent treatment. **Simple language version:** if it is compounded, mixed, or custom-dosed outside the labeled branded pathway, it should be understood as non-FDA-approved unless clearly documented otherwise. Sorting this out on your own is hard. It does not have to be. A focused visit with Dr. Caplan can clarify which medication is appropriate, what is actually approved, and what a realistic plan looks like for your situation. [Book a Starting Visit](/metabolic/metabolic-book/) ## Ways to obtain GLP-1 medications Not all access points are the same. The differences affect medication sourcing, safety, and how much guidance you receive along the way. ### Direct manufacturer or pharmacy-based access Prescriptions filled through standard pharmacies, sometimes with insurance or manufacturer-linked savings programs. - **Medication sourcing:** Usually FDA-approved branded medications - **Follow-up:** Ranges from minimal to moderate depending on the prescribing provider - **Strength:** Clear sourcing and standardized products - **Tradeoff:** Cost and coverage can be unpredictable without guidance ### Low-touch telehealth platforms Some platforms offer quick access and lower-friction onboarding, often using standardized protocols and streamlined follow-up. - **Medication sourcing:** May be FDA-approved or compounded depending on the program - **Follow-up:** Often protocol-driven with variable continuity - **Strength:** Convenience and speed - **Tradeoff:** Less individualized care and limited relationship depth Relationship-based clinical care ### Guided, personalized, physician-led Ongoing care with a physician who helps guide medication selection, dosing, and long-term planning and stays with you through the full course of treatment. [Continue with guided care with Dr. Caplan](/metabolic/metabolic-book/) - **Medication sourcing:** Prescriptions filled through standard pharmacies - **Follow-up:** Personalized, adaptive, and higher-touch - **Strength:** Nuanced decision-making, continuity, and real clinical relationship - **Tradeoff:** Visit costs are higher than low-touch options ### Compounding-focused programs Some programs center on compounded GLP-1 products or customized dosing approaches that differ from standard FDA-approved pathways. - **Medication sourcing:** Often compounded and not FDA-approved - **Follow-up:** Ranges from minimal to structured - **Strength:** Lower upfront cost and flexibility in some cases - **Tradeoff:** Less standardization, more variability in sourcing and oversight ## Monitoring and follow-up Some people want a simple prescription. Others want real clinical follow-up, especially through the first few months when nausea, constipation, food aversion, fatigue, reflux, dose tolerance, and adherence questions are most likely to surface. Lower-touch model ### Minimal follow-up This may work for experienced, uncomplicated patients, but it can leave significant value on the table, particularly in the early months. - Little real-time troubleshooting when symptoms arise - Dose increases may feel automatic rather than thoughtful - Less support for side effects, nutrition adaptation, or long-term sustainability Higher-touch model ### Guided early optimization This is often where better outcomes are shaped, especially early on. - Closer check-ins during the first months of treatment - Attention to tolerance, appetite, intake, hydration, bowel habits, and practical daily fit - Intentional titration rather than reflexive escalation to the next labeled dose - More help aiming for durable results rather than short bursts of rapid progress ### Early phase: first 1 to 3 months Often benefits from more frequent contact. This is when people are learning how the medication feels, how quickly to escalate, and whether the current formulation is even the right fit. ### Middle phase Once someone is tolerating treatment, the focus often shifts to dose matching, pace of progress, nutrition quality, hydration, and avoiding overly aggressive titration simply because the next dose exists. ### Maintenance phase Later care may be lighter in frequency, but it still matters. Goals may evolve from initial weight loss to durability, comfort, metabolic improvement, or preventing rebound weight gain. ## Duration of treatment There is no one universally correct treatment length. The right time horizon depends on response, goals, tolerability, affordability, comorbidities, and personal preference. ### Shorter-term use Some people use treatment for a defined window of months to create momentum, improve metabolic markers, or bridge toward new habits and a different weight set point. ### Longer-term maintenance Others stay on therapy for years or indefinitely, particularly when the medication is functioning more like chronic disease management than a temporary boost. Most clinical evidence suggests weight returns when the medication is stopped. ### Flexible or stop-start approaches Some people move in and out of treatment depending on cost, side effects, life demands, preferences, or changing goals. That can be done thoughtfully, but it benefits significantly from physician guidance. **Bottom line:** people do not all need the same molecule, the same dose, the same speed, the same format, or the same duration. Good care helps match the plan to the person and stays with them as that plan evolves. ## Still not sure which path makes sense for you? That is exactly what a physician-guided visit is for. You bring the questions. Dr. Caplan brings 20+ years of clinical experience and the time to actually work through them. ## Book with Dr. Benjamin Caplan, MD Board-certified family physician. Published in the New England Journal of Medicine. 350,000+ lifetime evaluations overseen. The same physician, every visit. ### GLP-1 Starting Visit / Onboarding $100.00 • 15 min Explore whether GLP-1 treatment is right for you. Review your health history, goals, and options and leave with a clear, thoughtful plan. [Book this visit](/metabolic/metabolic-book/) ### GLP-1 Early Check-In / Optimization $100.00 • 15 min Review appetite, progress, side effects, comfort, and tolerance. Decide together whether dose, timing, or formulation should change. [Book this visit](/metabolic/metabolic-book/) ### GLP-1 Progress + Maintenance $100.00 • 15 min Monitor progress, discuss changing needs or symptoms, and adapt the plan to support safe, durable success over the long term. [Book this visit](/metabolic/metabolic-book/) **Prefer a softer first step?** Start with the [brief intake form](/metabolic/metabolic-book/#step-1-intake) or [read the FAQ](/metabolic/metabolic-faq/) for answers to the most common questions before booking. ### Cite This Clinical Guide Caplan B. GLP-1 Medication Guide: Molecules, Dose Ladders, and Clinical Evidence. CED Clinic Metabolic Health Division; 2026. Available from: https://cedclinic.com/metabolic/metabolic-glp1-guide/. **Indexing Metadata:** Oxford CEBM Level 1A Systematic Review • Medical Specialty: Metabolic Medicine & Family Practice • Dr. Benjamin Caplan, MD (ABFM Diplomate, NPI 1962722637) ## Source note Medication availability, dose ladders, and access models change. This page is designed as a practical comparison tool and should be reviewed periodically. The FDA-approved product details summarized here were aligned to current FDA labeling and official company prescribing information at the time this page was prepared. - FDA prescribing information and official labeling for Wegovy (injection and tablets), including semaglutide strengths and maintenance dosing. - FDA prescribing information and official labeling for Zepbound and Mounjaro, including tirzepatide start and maintenance dosing. - FDA prescribing information and official labeling for Saxenda and Victoza, including liraglutide titration pathways. - FDA prescribing information and official labeling for Rybelsus, Ozempic injection, Ozempic tablets, and Foundayo oral tablets. - FDA safety communications on compounded and non-FDA-approved GLP-1 products (2025 and 2026). --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).